argenx logo

argenx

ARGX | NASDAQ
Chart Builder DCF Calculator
$950.95
-$9.09 (-0.95%)
At close: Nov 16, 2026, 4:00 PM ET
$950.95
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
-0.95%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
76.6
Fundamentals Excellent
Market Sentiment Bullish
Moat Narrow
Sector Rank #31/1021 (Top 3%)

Why Price Moved

7 days ago
+3.78%

Shares are trading higher after announcing the acq...

Key Statistics

Market Data

Market Cap $59.8B
1D Range
948.21 981.42
52W Range
663.93 1,058.90

Valuation (TTM)

PE 45.67
PB 7.10
EV/EBITDA 38.97

Valuation (NTM)

Forward PE 34.90
Forward PEG 0.72
Price Target $1,150.00
Loading financial charts...

Profile

argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company's operations span ...

Sector Healthcare
Industry Biotechnology
Employees 1,863
IPO Date May 18, 2017
Fiscal Year January - December

Latest News

3 Reasons Argenx Could Be a Top Biotech Stock for the Next Decade

8 days ago · fool.com

3 Reasons Argenx Could Be a Top Biotech Stock for the Next Decade
Unnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation Medicines

8 days ago · globenewswire.com

Unnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation Medicines
Best Biotech Stocks to Buy Now as AI Stocks Tank: ARGX

12 days ago · zacks.com

Best Biotech Stocks to Buy Now as AI Stocks Tank: ARGX
argenx to Present at Upcoming Investor Conferences

14 days ago · globenewswire.com

argenx to Present at Upcoming Investor Conferences
argenx: 3 Key Takeaways for Long-Term Investors

25 days ago · fool.com

argenx: 3 Key Takeaways for Long-Term Investors
argenx SE (ARGX) Q3 2026 Earnings Call Transcript

26 days ago · seekingalpha.com

argenx SE (ARGX) Q3 2026 Earnings Call Transcript
What argenex (ARGX) Said on Its Q3 Earnings Call

26 days ago · marketbeat.com

What argenex (ARGX) Said on Its Q3 Earnings Call
argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026

1 month ago · globenewswire.com

argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026
argenx Meets Primary Endpoint in Phase II Celiac Disease Study

1 month ago · zacks.com

argenx Meets Primary Endpoint in Phase II Celiac Disease Study
ARGX Stock Down on Stopping Late-Stage Autoimmune Disease Study

1 month ago · zacks.com

ARGX Stock Down on Stopping Late-Stage Autoimmune Disease Study

Earnings

Latest Earnings
Oct 22, 2026
EPS
$7.8
Beat +4.84%
REV
$2.82B
Beat +70.65%
Next Earnings
Feb 25, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
18
Consensus
Buy
Price Target
$1,150.00
Upside
+20.93%
Buy (16)
Hold (2)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.